Santa Clara, California (ots/PRNewswire) - Align Technology, Inc. (Nasdaq: ALGN), the inventor of Invisalign(R), a proprietary method of straightening teeth without wires and brackets, today announced that the San Francisco County Superior Court has granted a Temporary Restraining Order ("TRO") against defendants ...
Madrid, Spain (ots/PRNewswire) - PharmaMar announces that its second most advanced marine-derived anti-tumour agent, Aplidin(R), has commenced Phase II clinical trials in both prostate and bladder cancers. Phase II trial in Prostate Cancer This is the first trial of Aplidin in solid tumours to be carried out in the United States (US). This study will focus ...
Copenhagen, Denmark (ots/PRNewswire) - Gastrotech Pharma A/S announced today that Dr. Hans T. Schambye has been appointed as its Chief Executive Officer. He replaces Professor Claes Post who will continue to serve the company as a member of Gastrotech's Board of Directors and Senior Vice President. Dr. Post will focus entirely on identification and evaluation of ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the original target of 400 subjects for its Canadian Phase III psoriasis trial for its lead immunosuppressive compound, ISA247 has been reached. Due to the enthusiasm of our investigators and the willingness of patients to participate in the trial, the Company will allow approximately 80 ...
Bothell, Washington and Indianapolis, Indiana (ots/PRNewswire) - Lilly ICOS LLC (NYSE: LLY and Nasdaq: ICOS), marketer of Cialis(R) (tadalafil), a PDE5 inhibitor indicated for the treatment of erectile dysfunction (ED), is pleased with the European Patent Office's (EPO) final decision to affirm its earlier ...
Laval, Canada (ots/PRNewswire) - - Danish Contract Research Organization Will Help Double LAB Research's Revenues LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE), an integrated drug development company with a focus on inhalation delivery, today announced it has acquired all shares of Scantox, Biologisk Laboratorium A/S (Denmark), the leading Scandinavian, non- clinical contract research organization, for a total cash consideration of 28 million ...
San Diego, California and Reykjavik, Iceland (ots/PRNewswire) - - Continues Research to Validate Significance of SEQUENOM's Portfolio of Breast Cancer Genetic Discoveries SEQUENOM, Inc. (NASDAQ: SQNM) and Iceland Genomics Corporation (Iceland Genomics), a privately-held company, entered into a ...
Santa Clara, California (ots/PRNewswire) - Align Technology, Inc. (Nasdaq: ALGN), the inventor of Invisalign(R), a proprietary method of straightening teeth without wires and brackets, today filed a multi-claim lawsuit in San Francisco County Superior Court against defendants OrthoClear, Inc., OrthoClear Holdings, Inc., Muhammad Ziaullah Chishti, Bao Tran, Peter Riepenhausen, Joe Breeland, Jeff Tunnell, Christopher Kawaja, and Charles Wen. Among other things, the lawsuit ...
Carlsbad, California (ots/PRNewswire) - - Medex Commits More Than US$1.4 Million in Medical Product Contributions Medex, a global manufacturer and marketer of medical devices, announced today that it has authorized medical product donations of more than US$1.4 million to assist with relief efforts throughout tsunami-affected countries and other regions requiring assistance. Working through AmeriCares, ...
Basel, Switzerland (ots/PRNewswire) - - Study adds to the body of evidence showing the benefits of Avastin with different colorectal cancer treatment regimens A new study, presented for the first time today, shows Avastin(R) (bevacizumab, rhuMAb-VEGF) significantly increases survival in patients with ...
Basel, Switzerland (ots/PRNewswire) - - New data shows significant improvement in overall survival when Tarceva is added to chemotherapy New data, presented for the first time today, have shown that adding Tarceva (erlotinib) to chemotherapy improves survival in patients with locally advanced or metastatic pancreatic cancer(1). This is the second cancer type ...
St. Gallen, Switzerland (ots/PRNewswire) - In postmenopausal women with early breast cancer, letrozole offers better post-surgery protection against breast cancer recurrence than does tamoxifen, the current standard of care, according to data presented today at the Primary Therapy of Early Breast Cancer 9th ...
St. Gallen, Switzerland (ots/PRNewswire) - - Promising News for Breast Cancer Patients - Web Cast Briefing Available at http://www.ibcsg.org/index.shtm WHAT: BIG 1-98: First results and implications. A landmark, independent study found that letrozole, a leading aromatase inhibitor also known as Femara, demonstrated ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has completed recruitment for its Canadian Phase III psoriasis trial for its lead immunosuppressive compound, ISA247. Of the 400 subjects enrolled in the trial, 207 subjects have commenced treatment. The Company received a "No Objection Letter" from Health Canada on December 1, 2004 and commenced the trial on December 2, 2004. ...
Bothell, Washington and Indianapolis, Indiana (ots/PRNewswire) - - 2004 Worldwide Sales of Cialis Top US$550 Million - Lilly ICOS LLC (Lilly ICOS) (NYSE: LLY and Nasdaq: ICOS) is releasing its financial results for the fourth quarter and year ended December 31, 2004. Largely driven by the first year of sales in the United States, worldwide sales of Cialis(R) (tadalafil) surged 172% in 2004, to US$552 million, ...
Rochester, New York (ots/PRNewswire) - - Acquisition Broadens Kodak's CR Portfolio; Provides Foundation for Continued Growth - With Photo Eastman Kodak Company today announced it has entered into an agreement to acquire OREX Computed Radiography Ltd., a leading provider of compact, robust computed radiography systems that enable medical practitioners to ...
Madrid, Spain (ots/PRNewswire) - PharmaMar announced today that Zalypsis(R) (PM00104/50), its fifth new marine derived compound, has begun Phase I clinical trials, already in patients, for the treatment of solid tumours. Zalypsis is a novel chemical entity related to the marine natural compounds Jorumycin and the family of Renieramycins, obtained from molluscs ...
Paris (ots/PRNewswire) - - Menactra Vaccine is Safe and Effective in Preventing Potentially Deadly Meningococcal Disease Sanofi pasteur, the vaccines business of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has licensed Menactra(TM) (Meningococcal [Groups A, ...
Basel, Switzerland (ots/PRNewswire) - - First Treatment of its Kind With Proven Survival Benefit for Patients With Advanced Colorectal Cancer Roche today announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metastatic colorectal cancer. Roche will now make Avastin available ...
Phuket, Thailand (ots/PRNewswire) - The Thai government is in the process of establishing an international standard post mortem and ante-mortem identification centre in Phuket as the processing of victims of the tsunami that hit Thailand gets underway. There are now disaster victim identification (DVI) teams from 19 countries in Thailand working under the command of General Nopadol of the Royal Thai Police, the ...
Zurich, Switzerland (ots/PRNewswire) - Baxter Healthcare S.A. announced today that the European Commission has granted expanded approval of ADVATE(R) (Octocog Alfa Recombinant Coagulation Factor VIII), for use in children with haemophilia A under six years of age. This expanded approval was granted on the ...
Abbott Park, Illinois (ots/PRNewswire) - - HUMIRA Data Shows Slowed Joint Damage in Pivotal Study Abbott (NYSE: ABT) announced it has simultaneously submitted a Type II Variation to the European Medicines Agency (EMEA) and a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug ...
Abbott Park, Illinois (ots/PRNewswire) - - First expansion into new disease for rheumatoid arthritis drug HUMIRA Abbott (NYSE: ABT) announced it has simultaneously submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) and a supplemental Biologics License Application ...
London (ots/PRNewswire) - AstraZeneca today announced that the initial analysis of the primary endpoint of Study 709, IRESSA Survival Evaluation in Lung cancer (ISEL) with 1692 patients has been conducted, and shows that IRESSA failed to significantly prolong survival in comparison to placebo in the overall ...
London (ots/PRNewswire) - - 'Redefining Hope and Beauty' Campaign Surpasses All Expectations Breast cancer charities from around the world are today celebrating the success of the world's first truly global breast cancer awareness campaign - 'Redefining Hope and Beauty'. In the first few weeks since its historic launch, the campaign has already surpassed ...
Montreal, Canada (ots/PRNewswire) - Galileo Genomics Inc., a Montreal-based gene and drug target discovery company, announced today it raised CDN$11.1 million in additional equity funding to close the 2nd tranche of its Series B financing. This round, originally targeted at CDN$10 million, is the latest in a ...
San Antonio Breast Cancer Symposium, California (ots/PRNewswire) - - New Results From Two Phase II Trials Demonstrate Efficacy and Tolerability for 'Faslodex' Following Progression on aromatase Inhibitor Therapy - Webcast of Data Available on www.astrazenecapressoffice.com Important new data from two studies presented at the 27th Annual San Antonio Breast ...
San Antonio, Texas (ots/PRNewswire) - - New Trial Results Offer More Choice for More Women With Breast Cancer The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Completed Treatment Analysis(1),(2): Presented by Professor Anthony Howell and simultaneously published via fast-track peer-review in ...
San Antonio, Texas (ots/PRNewswire) - - 'The Latest Hormonal Treatment Options in the Breast Cancer Continuum' - An AstraZeneca Sponsored Webcast From the 2004 San Antonio Breast Cancer Symposium This webcast will announce key new data for 'FASLODEX' and 'ARIMIDEX' that is being presented at the 27th San Antonio Breast Cancer Symposium (SABCS), 8 - 11 December. The webcast explores the latest developments in the treatment of postmenopausal women with early ...
Laval, Quebec (ots/PRNewswire) - LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE), an integrated drug development company focused on the inhalation market, today announced that its shares are available for trading on the Regulated Unofficial Market (Freiverkehr) of the Frankfurt Stock Exchange and on XETRA(R), the Deutsche Borse AG electronic trading system. The inclusion of LAB's securities in the ...